Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects
Completed
Amgen
Phase 2
2011-07-28
The primary objective was to evaluate the effect of 12 weeks of subcutaneous evolocumab (AMG
145), compared with ezetimibe, on percent change from baseline in low-density lipoprotein
cholesterol (LDL-C) in patients with hypercholesterolemia unable to tolerate an effective
dose of a statin.
Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels
Completed
Amgen
Phase 2
2011-07-06
The primary objective was to evaluate the effect of 12 weeks of subcutaneous evolocumab (AMG
145) every 2 weeks (Q2W) or every 4 weeks (Q4W), compared with placebo, on the percent change
from baseline in LDL-C when used as monotherapy in adults with hypercholesterolemia.
Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study
Completed
Amgen
Phase 3
2012-01-05
To evaluate the efficacy, safety, and tolerability of 52 weeks of subcutaneous (SC)
evolocumab (AMG 145) compared with placebo when added to assigned background lipid-lowering
therapy.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
